Combined treatment for small cell lung cancer

Abstract

Small cell lung cancer (SCLC) accounts for approximately 15 % of all lung cancer cases. The prognosis for patients with MRL is unfavorable: the 5-year survival rate is less than 10 %. Due to the limited and low effectiveness of treatment options for SCLC, the search for more effective therapeutic approaches does not weaken. However, despite decades of basic and clinical research, little progress has been made in the treatment of MRL SCLC, leading to one of the most intractable diseases in clinical practice. In this regard, in recent years, the question arises of the need to consider the possibilities and options for combined treatment in small cell lung cancer.